Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
68.52
USDSponsored
-0.46
-0.67%
May 21, 16:00 UTC -4
Closed
After-Market
68.01
-0.51
-0.74%
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 31 of 42 last estimates.
74%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$409.07M
/$1.85
Implied change from Q1 26 (Revenue/ EPS)
+8.59%
/+15.63%
Implied change from Q2 25 (Revenue/ EPS)
+25.59%
/+20.13%
Halozyme Therapeutics, Inc. earnings per share and revenue
On May 11, 2026, HALO reported earnings of 1.60 USD per share (EPS) for Q1 26, beating the estimate of 1.56 USD, resulting in a 2.52% surprise. Revenue reached 376.71 million, compared to an expected 366.23 million, with a 2.86% difference. The market reacted with a +6.81% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 1.85 USD, with revenue projected to reach 409.07 million USD, implying an increase of 15.63% EPS, and increase of 8.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Halozyme Therapeutics, Inc. reported EPS of $1.60, beating estimates by 2.52%, and revenue of $376.71M, 2.86% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved up 6.81%, changed from $66.41 before the earnings release to $70.93 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $1.85 and revenue of $409.07M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement